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Background & Aims: Posttranslational farnesylation is
required for Ras activation. Farnesyl transferase inhibi-
tors (FTIs) selectively block protein farnesylation and
reduce the growth of many Ras-transformed cells in
vitro and in vivo. Activated Ras transforms rat intestinal
epithelial (RIE-1) cells by a mechanism distinct from
NIH 3T3 fibroblasts in that an epidermal growth factor
receptor (EGFR) autocrine loop contributes signifi-
cantly to the Ras-transformed RIE-1 phenotype.
Methods: The ability of FTIs to block growth of Ras-
transformed RIE-1 cells was evaluated, and these
results were correlated with decreased EGFR ligand
production. Results: FTI L744,832 caused a selective,
dose-dependent, reversible blockade in proliferation of
H-Ras–transformed RIE-1 cells, whereas control cell
lines, K-Ras–transformed cells, and activated raf-
transfected RIE cells were unaffected. The growth-
inhibitory effects of L744,832 correlated with loss of
farnesylated H-Ras protein and a marked reduction in
transforming growth factor (TGF)-a and amphiregulin
expression. Inhibition of proliferation of H-Ras RIE-1
cells by L744,832 was overcome by exogenous TGF-a,
and enhanced growth inhibition was achieved by EGFR
blockade in combination with L744,832. Conclusions:
These data suggest that one mechanism by which FTIs
inhibit growth of H-Ras–transformed epithelial cells is
by reducing Ras-induced EGFR ligand production.
Many cellular proteins undergo posttranslationalmodification by farnesyl transferase (FTase)1 or
geranylgeranyl-protein transferases (GGPTase I and II).2–4
Although a variety of proteins such as K-Ras, H-Ras,
N-Ras, Rho B, and nuclear lamins A and B are farne-
sylated, a greater number of proteins undergo geranylger-
anylation.5 Farnesylation of Ras by FTase is required for
translocation of the protein to cellular membranes and its
subsequent activation.6,7 FTase adds a 15-carbon isopre-
nyl group through a thioether linkage to the C-terminal
CAAX box of Ras.1
Because Ras mutations occur in many human tumors,
including adenocarcinomas of the pancreas and colon,8–10
specific FTase inhibitors (FTIs) have been developed as
anticancer drugs to target tumors in which Ras proteins
have undergone mutational activation.11–15 Pharmacologi-
cal inhibition of FTase has been shown to inhibit Ras in
both H- and K-Ras–transformed cells, although in most
cell types, K-Ras is far less sensitive.11,12,15–19 Resistance
of K-Ras to FTIs may occur because of its compensatory
geranylgeranylation by GGPTase I.20 Unexpectedly, FTIs
have no apparent growth-inhibitory effect on normal
cells,11,12 and inhibition of cells by FTI does not always
correlate with Ras mutational status.19 These observa-
tions indicate that further study is required to fully
understand and delineate the effects of FTIs in tumor
biology.
We previously found that mutant Ras causes transfor-
mation of intestinal and mammary epithelial cells via
pathways and mechanisms distinct from those described
for fibroblasts.21,22 For example, activated Ras trans-
formed the rat intestinal epithelial cell line RIE-1 and the
mammary epithelial line MCF-10A, whereas activated
Raf did not, leading to the conclusion that pathways
independent of the conventional Raf/MAPKK (mitogen-
activated protein kinase kinase)/MAPK) pathway contrib-
ute to Ras transformation of epithelial cells.21,23 One such
pathway is Ras-stimulated increased production and
secretion of epidermal growth factor receptor (EGFR)
ligands.21,22 Blockade of EGFR signaling reverts the
Abbreviations used in this study: AR, amphiregulin; DMSO, di-
methyl sulfoxide; EGF, epidermal growth factor; EGFR, EGF receptor;
FTase, farnesyltransferase; FTI, FTase inhibitor; GGPTase, geranyl-
geranyl-protein transferase; HB-EGF, heparin-binding EGF-like growth
factor; MAPK, mitogen-activated protein kinase; RIA, radioimmuno-
assay; SDNS-PBS, phosphate-buffered saline containing 0.02%
saponin and 5% normal donkey serum; SDS-PAGE, sodium dodecyl
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transformed appearance of Ras-transformed RIE-1 cells
and prevents morphological transformation of parental
RIE-1 cells caused by Ras-conditioned medium.22 These
data indicate that Ras transformation of RIE-1 cells is
mediated, at least in part, by EGFR ligand production
acting via autocrine pathways.
In this study, we determined that the FTI designated
L744,832 significantly inhibits the growth of H-Ras–
transformed RIE-1 cells by blocking production of EGFR
ligands induced by Ras transformation. The proliferation
of control cells, activated Raf-transfected cells, and
K-Ras4B–transformed RIE-1 cells is unaffected by
L744,832 treatment even at concentrations as high as 50
µmol/L. L744,832 causes a selective, dose-dependent,
reversible reduction in transforming growth factor
(TGF)-a and amphiregulin (AR) expression and cell
growth only in H-Ras–transformed RIE-1 cells. FTI
growth inhibition is preceded by a loss of farnesylated
Ras protein and subsequent reduction in Ras-mediated
EGFR ligand production. Growth inhibition induced by
FTI in H-Ras RIE cells is overcome by addition of
exogenous TGF-a. Blockade of EGFR signaling by a
specific EGFR tyrosine kinase inhibitor (PD153035)
reduces the growth of H-Ras and K-Ras4B–transformed
RIE-1 cells and enhances the growth-inhibitory effects of
L744,832, further supporting reduction in EGFR ligand




L744,832 and PD153035 were obtained from Merck
Research Laboratories (West Point, PA)24 and Parke-Davis
Pharmaceutical Research (Ann Arbor, MI),25 respectively.
L774,832 and PD153035 were dissolved in dimethyl sulfoxide
(DMSO) at a 10003 concentration and stored at 220°C.
Radionucleotides were purchased from New England Nuclear
(Boston, MA). All other reagents were analytical grade and
purchased from standard suppliers.
Cell Culture
RIE-1 cells, obtained from Dr. Kenneth Brown (Cam-
bridge, England), are a diploid, nontransformed, EGF-
responsive cell line derived from rat small intestine.26,27 RIE-1
cells stably transfected with control vector construct Neo4F
and with constructs encoding activated Raf, H-, and K-Ras4B
have been described previously.21,22 Stably transfected cells
were maintained in growth medium containing 500 µg/mL of
G418 (Sigma Chemical Co., St. Louis, MO).
[3H]Thymidine Incorporation
DNA replication was assayed using 10,000 cells/well
seeded in 24-well plates. Twenty-four hours after plating,
cultures were treated with the indicated concentrations of
drug. After a 22-hour incubation, cells were pulsed with 1
µCi/well of [3H]thymidine (Amersham, Arlington Heights, IL)
for 2 additional hours. Medium was removed, and each well
was washed 3 times for 5 minutes with 1 mL/well of cold 10%
trichloroacetic acid. Plates were dried for 30 minutes at room
temperature, and 300 µL/well of 0.2N NaOH and 40 µg/mL
salmon sperm DNA were added. After a 30-minute incubation
at room temperature, each sample was transferred into scintilla-
tion vials containing 5 mL of aqueous scintillation cocktail and
counted for 1 minute. For time course experiments, cells were
fixed by addition of 300 µL of 1 mol/L ascorbic acid into the
medium of each well. All wells were processed at the comple-
tion of the experiment as described above. Results were
normalized to cell number that was determined in replicate
wells for each condition. Unless otherwise stated, all results are
representative of at least 3 separate experiments.
TGF-a Radioimmunoassay
The radioimmunoassay (RIA) for TGF-a was per-
formed in conditioned medium as described previously.28
Unless otherwise stated, all results presented are representative
of at least 3 separate experiments.
Isolation of Poly(A) RNA and Northern
Blot Analysis
Cells were grown to near confluence, washed twice
with isotonic buffer, and then switched to serum-free Dulbec-
co’s modified essential medium for 72 hours. Total cellular
RNA was extracted by the method of Schwab et al.29 Oligo(dT)-
selected RNA was separated by electrophoresis in 1.2%
agarose/formaldehyde gels, and Northern blot analysis was
performed.30,31 Hybridizations, with species-specific probes
labeled by RNA polymerase-directed reverse transcription
(EGF, TGF-a, AR, and 1B15) or random primer extension
(heparin-binding EGF-like growth factor [HB-EGF]), were
performed in hybridization ovens as described previously.32,33
1B15 is a constitutively expressed sequence used to assure
equivalent loading and transfer of messenger RNA (mRNA).34
Band intensities were quantified by phosphorimager analysis
(Molecular Dynamics, Sunnyvale, CA). Unless otherwise stated,
all results are representative of at least 3 separate experiments.
Ras Protein Processing
Cells were plated into 12-well plates at 10,000 cells/
well. Cells were treated with 10 nmol/L, 100 nmol/L, or 1
µmol/L L744,832 for the indicated times and harvested in 100
mL sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer. The method for analyzing Ras
processing has been described in detail.35 Briefly, samples were
separated by 10% SDS-PAGE and transferred to Immobilon
(Millipore, Bedford, MA) by Western blotting. Ras proteins
were detected by the H-Ras–specific antibody 146-3E4 (Qual-
ity Biotech, Camden, NJ) using a peroxidase-conjugated
secondary antibody followed by enhanced chemiluminescence
(Amersham, Arlington Heights, IL) detection and quantitation
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with a Bio-Rad phosphorimager (Hercules, CA). Unless other-
wise stated, all results presented are representative of at least 3
separate experiments.
Ras Protein Immunofluorescence
Cells were plated onto autoclaved coverslips at 10,000
cells/coverslip. Cells were treated for 24 hours with 100
nmol/L, 1 µmol/L, or 10 µmol/L L744,832 and fixed in 2%
paraformaldehyde for 20 minutes at room temperature. The
method for Ras immunofluorescence was adapted from previ-
ous methods.35 Briefly, coverslips were washed 3 times with
phosphate-buffered saline (PBS) and permeabilized and blocked
in PBS containing 0.02% saponin and 5% normal donkey
serum (SNDS-PBS) for 30 minutes at room temperature. The
coverslips were incubated with the primary pan-Ras antibody
Y13259 (Oncogene Science, Manhasset, NY) at 30 µg/mL in
SNDS-PBS for 1 hour at room temperature. Coverslips were
washed 3 times for 10 minutes with PBS containing 0.02%
saponin. The coverslips were incubated with secondary anti-
body fluorescein isothiocyanate–conjugated donkey anti-rat
immunoglobulin G (Jackson Laboratories, West Grove, PA) at
10 µg/mL in SNDS-PBS for 30 minutes at room temperature,
and 48,6-diamidino-2-phenylindole dihydrochloride (DAPI)
was added at 5 µg/mL to label nuclei during the last 5 minutes
of the incubation. Coverslips were washed 3 times for 10
minutes with PBS containing 0.02% saponin and mounted for
immunofluorescence and visualization.
Results
FTI Selectively Blocks H-Ras RIE-1
Cellular Proliferation
Initial studies were designed to test the effect of
FTI L744,832 on growth of parental RIE-1 cells and
RIE-1 cells stably transfected with activated raf and ras
complementary DNA constructs. L744,832 (from 100
nmol/L to 50 µmol/L) selectively inhibited proliferation
of activated H-Ras–transfected RIE-1 cells as measured
by a dose-dependent reduction in [3H]thymidine incorpo-
ration (Figure 1), number of cells (data not shown), and
S-phase cell population by flow cytometry (data not
shown). No indication of apoptotic cell death was
apparent in flow cytometric analysis of FTI-treated
H-Ras RIE-1 cells. Proliferation of parental RIE-1 cells,
vector-transfected cells, and activated raf-transfected RIE-1
cells was unaffected at FTI concentrations as high as 10
µmol/L (Figure 1). Further assays showed that concentra-
tions as high as 50 µmol/L FTI had no significant effect
on proliferation of these cells (data not shown). These data
are consistent with the reported absence of toxicity in
FTI-treated animals, as well as FTI resistance in normal
cells and cells transfected with oncogenes downstream of
Ras.11,12,15–18 Proliferation of K-Ras4B–transformed
RIE-1 cells was not affected by FTI up to 50 µmol/L, but
reduction of proliferation at doses higher than 50 µmol/L
was observed because of cytotoxicity (data not shown).
FTI Blocks Ras-Induced TGF-a
and AR Growth Factor Expression
Inasmuch as Ras transformation of RIE-1 cells is
associated with induction of EGFR ligands and signaling
through the EGFR contributes significantly to the
Ras-transformed phenotype,21,22 we examined the effects
of FTI on EGFR ligand production in Ras-transformed
RIE-1 cells. As shown in Figure 2, treatment of H-Ras
RIE-1 cells for 24 hours with L744,832 caused a
dose-dependent decrease in TGF-a protein levels in the
culture medium (Figure 2A); this decrease correlated
with a parallel reduction in DNA synthesis (Figure 1).
Under these experimental conditions, L744,832 had no
effect on TGF-a protein levels in the culture medium of
FTI-resistant K-Ras4B RIE-1 cells (Figure 2B), nor on
mitogenesis (Figure 1). As shown in Figure 3, a single
Figure 1. Effect of L744,832
on DNA replication in control
and oncogene-transfected RIE-1
cells. Cells were plated at
10,000 cells/well in 24-well
cluster plates. Near-confluent
cells were treated for 24 hours
with the indicated concentra-
tions of FTI or vehicle (DMSO, 1
µL/mL). During the last 2 hours
of the incubation, cells were
pulsed with [3H]thymidine (1
µCi/mL) and processed as de-
scribed in Materials and Meth-
ods. Number of cells was deter-
mined in replicate wells to
normalize data.
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administration of L744,832 also blocked accumulation of
TGF-a in the medium of H-Ras RIE-1 cells. Steady-state
mRNA expression of EGFR ligands was examined by
Northern blot analysis. Dose-dependent decreases in
transcripts for TGF-a and AR mRNA were observed
after a 24-hour exposure to FTI; for example, at 10
µmol/L L744,832, TGF-a and AR signals were decreased
by approximately 80% and 95%, respectively (Figure
4A). No reduction in TGF-a and AR mRNA expression
was observed in FTI-resistant K-Ras4B–transformed
RIE-1 cells (Figure 4B).
FTI Growth Inhibition Is Temporally
Associated With Decreased TGF-a
and AR Expression
We examined the temporal relationship between
down-regulation of EGFR ligands and decreased prolifera-
tion in FTI-treated H-Ras RIE-1 cells. Administration of
a single dose of L744,832 resulted in a rapid decrease in
both TGF-a and AR mRNA. This was observed as early
as 3 hours, was maximal at 24 hours, and recovered
between 72 and 96 hours (Figure 5). L744,832-mediated
reduction of TGF-a and AR mRNA was not affected by
cycloheximide treatment (data not shown). The reduction
in TGF-a and AR mRNA expression preceded the
decrease in cellular proliferation that began to decrease
significantly at 12 hours with maximal inhibition at 24
hours and recovery only starting at 96 and 120 hours after
FTI treatment (Figure 5).
FTI Rapidly Inhibits H-Ras Farnesylation
and Membrane Localization
The rapidity with which L744,832 reduced EGFR
ligand mRNA expression was unexpected because previ-
ous studies have described a Ras half-life of 20–24 hours
in fibroblasts.36 However, the half-life of Ras is dramati-
cally reduced in FTI-treated H-Ras–transformed RIE-1
cells compared with FTI-treated NIH 3T3 fibroblasts (A.
Cox, C. Der, and R. Coffey, unpublished observations,
June 1998). We determined the effect of a single dose of
L744,832 (1 µmol/L) on H-Ras farnesylation over time
(Figure 6A). There was a 50% decrease in farnesylated
Ras after 3 hours of FTI treatment. This decrease
correlates with a similar reduction in TGF-a and AR
mRNA expression 3 hours after L744,832 administration
(Figure 5). By 24 hours, most of the Ras protein was
unfarnesylated and remained in that form at 48 hours.
Most Ras protein returned to its farnesylated form by 72
hours (data not shown). At 24 hours, we compared a
dose-range effect of L744,832 on Ras processing in
H-Ras and K-Ras4B RIE-1 cells (Figure 6B). There was a
dose-dependent decrease in the amount of farnesylated
Ras by FTI in H-Ras RIE-1 cells but not in K-Ras4B
RIE-1 cells. The farnesylation of K-Ras4B was not
affected by L744,832 in concentrations up to 50 µmol/L
(data not shown), a finding that is consistent with its lack
of an effect on cellular proliferation at this dose. Western
blotting using a pan-Ras antibody showed equal inten-
sity of the p21 Ras signal in H- and K-Ras4B–
Figure 2. L744,832 reduces
TGF-a protein levels in (A) H-Ras
RIE-1 cells but not in (B) K-Ras4B
RIE-1 cells. Under experimental
conditions described in Figure
1, medium was removed, and
TGF-a protein concentrations
were determined by RIA as de-
scribed in Materials and Methods.
Figure 3. L744,832 prevents the accumulation of TGF-a protein in the
conditioned medium of H-Ras RIE-1 cells. Cells were plated at 10,000
cells/well in 24-well cluster plates. Near-confluent cells were placed in
serum-free medium for 24 hours. FTI (10 µmol/L; N) or vehicle
(DMSO, 1 µL/mL; s) was added to each well; conditioned medium
was collected at the indicated times after FTI addition; and TGF-a
protein concentrations were determined by RIA. Number of cells was
determined in replicate wells to normalize data.
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transformed cells, whereas the signal in parental RIE-1
cells was barely detectable (data not shown). The immu-
nolocalization of Ras in response to FTI treatment was
also examined (Figure 6C). Treatment with L744,832 (10
µmol/L) resulted in loss of H-Ras membrane localization,
but not K-Ras4B localization, again supporting a differ-
ential effect of FTI on cellular proliferation and Ras protein
farnesylation in H- and K-Ras4B–transformed cells.
Addition of TGF-a Overrides
FTI Growth Inhibition
TGF-a was administered to L744,832-treated
H-Ras RIE-1 cells to further address the importance of
decreased EGFR ligand expression in FTI-mediated
growth inhibition. Addition of TGF-a (20 ng/mL)
simultaneous with or 24 hours after L744,832 fully
reversed growth inhibition (Figure 7) and partially
restored growth in soft agar (data not shown). Further-
more, coadministration of a TGF-a–neutralizing anti-
body blocked the ability of TGF-a to restore proliferation
in FTI-treated H-Ras RIE-1 cells (Figure 7). These
results suggest that down-regulation of EGFR ligand
expression in H-Ras–transformed RIE-1 cells by L744,832
plays a central role in the growth inhibition achieved by
this compound. However, this may not be the drug’s sole
mechanism of action because L744,832 treatment of
H-Ras–transformed RIE-1 cells for 24 hours resulted in a
reduction in MAPK activity, leaving open the possibility
that other Ras effectors are also involved. Interestingly,
pretreatment of parental RIE-1 cells with FTI had no
effect on unstimulated proliferation (Figure 1). L744,832
only partially inhibits (20%–30%) TGF-a–stimulated
proliferation and fails to block TGF-a–stimulated induc-
tion of EGF-related peptides in parental RIE-1 cells
(Barnard et al.37 and data not shown). The relative
inability of FTI to block these events in normal RIE-1
cells suggests that they are mediated by K-Ras signaling
or by a Ras-independent pathway.
Enhanced Growth Inhibition
of Ras-Transformed Cells
by Ras and EGFR Blockade
K-Ras–transformed fibroblasts38,39 and epithelial
cells (Figure 1) are more resistant to FTI growth inhibi-
Figure 4. L744,832 decreases TGF-a and AR mRNA expression in (A)
H-Ras RIE-1 cells but not in (B) K-Ras4B RIE-1 cells. Cells were plated
at 1 3 106 cells/flask in T75 flasks. When cells reached 70%–80%
confluency, the cultures were treated with the indicated concentration
of FTI or vehicle (DMSO, 1 µL/mL) for 24 hours. The cells were then
lysed and processed for Northern blot analysis as described in
Materials and Methods. 1B15 is a constitutively expressed gene that
is used to assure equivalent loading and transfer of RNA.
Figure 5. Temporal effect of 10 µmol/L L744,832 on EGFR ligand
expression and mitogenesis in H-Ras RIE-1 cells. Experimental condi-
tions and analysis of Northern blots and DNA replication were similar
to those described in Figures 4 and 1, respectively. During the time
course for DNA replication, 300 µL of 1 mol/L ascorbic acid was added
into the medium of each well after a 2-hour pulse of [3H]thymidine for
each time point, and all wells were processed together at the
completion of the assay. The effects on DNA replication are expressed
as percent of control.N, TGF-a; s, AR; d, [3H]thymidine.
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B
Figure 6. Treatment with L744,832 causes rapid accumulation of unfarnesylated Ras and loss of cell surface association in H-Ras RIE-1 cells. (A)
H-Ras RIE-1 cells were plated at 104 cells/well in 12-well cluster dishes. When 70% confluent, cells were treated with L744,832 (1 µmol/L) or
vehicle (DMSO, 1 mg/mL) for the indicated times. Cells were then collected into SDS-PAGE sample buffer for Western blotting as described in
Materials and Methods. Data are presented as percentage processed (that is, farnesylated) Ras normalized to untreated controls. (B) Under
similar conditions, H-Ras and K-Ras4B RIE-1 cells were treated with increasing concentrations of L744,832 for 24 hours. Fully farnesylated (P)
Ras protein migrates faster than the unfarnesylated (U) form. This experiment is representative of 2 separate experiments performed with 3
different concentrations of inhibitor. (C) H- and K-Ras4B RIE-1 cells were plated on coverslips in 12-well cluster dishes. When 70% confluent, cells
were treated with FTI (10 µmol/L) or vehicle (DMSO, 1 mg/mL) for 24 hours, and immunofluorescence for Ras protein was performed as described
in Materials and Methods. Ras protein is labeled green and nuclei are labeled blue.
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tion than H-Ras–transformed cells. Because K-Ras muta-
tions occur more commonly in human gastrointestinal
neoplasia, we considered whether blockade of EGFR
signaling by use of a specific EGFR tyrosine kinase
inhibitor (PD153035) might enhance the growth-
inhibitory effect of FTI in K-Ras4B–transformed RIE-1
cells.22 Treatment of both H-Ras– and K-Ras4B–
transformed RIE-1 cells with PD153035 alone caused a
dose-dependent decrease in DNA synthesis (Figure 8A).
This occurred without a change in MAPK activation,
indicating that EGFR-mediated growth occurs, at least
in part, by a pathway independent of the canonical
Ras/Raf/MAPKK/MAPK cascade. When H- and
K-Ras4B–transformed RIE-1 cells were treated simulta-
neously with L744,832 and PD153035, there was en-
hanced growth inhibition of both lines (Figure 8B).
Discussion
The development of FTIs has provided an impor-
tant tool for studying Ras function and signal transduc-
tion. Although FTIs are effective inhibitors of H-Ras
transformation in vitro and in vivo,11–18 the lack of an
effect in K-Ras–transformed cells and the apparent lack
of effects on normal cell signaling suggest that further
study of mechanisms underlying FTI drug action is
needed. We previously found that activated Ras is
capable of transforming RIE-1 cells, whereas activated
Raf is not. This contrasts with observations in 3T3
fibroblasts in which both Ras and Raf are transforming.21
These observations suggest that Ras transformation in
epithelial cells involves additional Ras effector pathways.
One such potential pathway is induction of EGF-related
peptides; e.g., TGF-a, AR, and HB-EGF. In prior
studies, we found that these growth factors are secreted
into the conditioned medium of H- and K-Ras4B–
transformed RIE-1 cells and are capable of causing
morphological transformation and soft agar growth of
parental RIE-1 cells.21,22 EGFR blockade partially reverts
the transformed morphology of Ras RIE-1 cells and
prevents the morphological transformation of parental
RIE-1 cells caused by Ras-conditioned medium.22
Using transfected RIE-1 cells, we explored the effect of
the FTI L744,832 on Ras-induced EGFR ligand produc-
tion. We show now that K-Ras4B–transformed intestinal
epithelial cells, like K-Ras–transformed fibroblasts38,39
are more resistant to growth inhibition by L744,832 than
H-Ras–transformed cells. This resistance may be due to a
100-fold greater binding affinity between K-Ras and
FTase than H-Ras, or that K-Ras may be a substrate for
Figure 7. Exogenous TGF-a overrides FTI growth inhibition of H-Ras
RIE-1 cells. Cells were plated at 10,000 cells/well in 24-well cluster
plates. Near-confluent cells were treated for 24 hours with the
indicated concentrations of FTI or vehicle (DMSO, 1 µL/mL). Cells
were then treated for an additional 24 hours with TGF-a (10 ng/mL),
TGF-a–neutralizing antibody (S574, 3 µg/mL), or a nonspecific anti-
body of the same type and species (NS, 3 µg/mL). During the last 2
hours of the final incubation, cells were pulsed with [3H]thymidine and
then processed as described in Materials and Methods. Number of
cells was determined in replicate wells to normalize data.
Figure 8. Effects of a specific EGFR tyrosine kinase inhibitor
PD153035 (TKI) alone and in combination with L744,832 (FTI) on DNA
synthesis in Ras-transformed RIE-1 cells. Cells were plated at 10,000
cells/well in 24-well cluster plates. (A) H- and K-Ras4B RIE-1 cells
were treated for 24 hours with the indicated concentrations of TKI or
vehicle (DMSO, 1 µL/mL). (B) H- and K-Ras4B RIE-1 cells were treated
with 10 µmol/L FTI and 1 µmol/L TKI alone and in combination or with
vehicle (DMSO, 2 µL/mL), when they had reached 70%–80% conflu-
ency. During the last 2 hours of the incubation, cells were pulsed with
[3H]thymidine and then processed as described in Materials and
Methods. Number of cells was determined in replicate wells to
normalize data.
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compensatory geranylgeranylation in the absence of
farnesylation.38–42 In fact, an inhibitor of GGPT I
disrupts oncogenic K-Ras processing and signaling.37
Parental RIE-1 cells, as well as control transfectants and
activated Raf-transfected RIE-1 cells, are unaffected by
L744,832 treatment, consistent with previous reports
showing that normal cells and cells transfected with
oncogenes downstream of Ras signaling are resistant to
the effects of FTIs.11–18
The specificity of FTIs for transformed cells is puzzling
because Ras function is important in normal mitogenic
signaling and is dependent on farnesylation. It is feasible
that normal Ras signaling occurs by geranylgeranylated
K-Ras in the presence of FTase inhibition.20,38–42 Alterna-
tively, normal mitogenic signaling may be mediated
through pathways distinct from Ras in some cell types.19
We observed that L744,832 has no effect on unstimu-
lated parental RIE-1 cellular proliferation and only
partially inhibits TGF-a–stimulated proliferation. Inter-
estingly, FTIs also block the growth of a variety of tumor
cells without Ras mutations. It is possible that this occurs
because activated receptor tyrosine kinases constitutively
activate Ras that is then inhibited by FTIs,19 or that FTI
inhibits TGF-a and AR expression, as shown in the
present study. In support of this, we recently reported
that FTI L744,832 decreases levels of TGF-a in mam-
mary cystic fluid and inhibits the growth of mammary
tumors in MMTV-TGFa transgenic mice.43
L744,832 appears to selectively block anchorage-
dependent proliferation of H-Ras–transformed RIE-1
cells by inhibiting Ras-mediated EGFR ligand produc-
tion. Mammalian EGFR ligands include TGF-a, AR,
EGF, HB-EGF, betacellulin, and epiregulin.44 Of these
EGFR ligands, TGF-a, AR, and HB-EGF are induced
upon Ras-transformation of RIE-1 cells.22 L744,832
causes inhibition of TGF-a and AR production, which
correlates with a parallel loss of functional farnesylated
H-Ras protein and its plasma membrane association. In
addition, inhibition of proliferation of H-Ras RIE-1 cells
by FTI is overcome by addition of TGF-a. FTI-induced
loss of farnesylated oncogenic H-Ras protein also lowers
MAPK activation; therefore, it is likely that decreases in
MAPK activity also contribute to FTI growth inhibition
in these cells. However, the ability of the specific EGFR
TKI to decrease cellular proliferation in the absence of
reduced MAPK activity and the enhanced growth inhibi-
tion observed with blockade of both Ras and EGFR
signaling emphasize the importance of EGFR signaling
to proliferation of Ras-transformed RIE-1 cells. These
data suggest that one mechanism of FTI action on
Ras-transformed epithelial cells is to block EGF-like
autocrine growth factor pathways induced by Ras transfor-
mation. The ability of EGFR blockade to enhance FTI
growth inhibition of K-Ras–transformed cells has clinical
implications. It is likely that other agents will need to be
administered with FTIs to achieve antitumor efficacy
because their effects appear cytostatic.45
Selected tumor cell lines with activating Ras muta-
tions have been shown to be relatively resistant to effects
of L744,832.19 In these resistant cell lines, FTI did not
inhibit MAPK activation in response to growth factor
stimulation as it did in sensitive lines.19 Other effects of
FTI, such as those on transformed morphology, do not
correlate well with the time course of inhibition of Ras
farnesylation.16 However, some FTI effects on morphol-
ogy may also be mediated, at least partly, by the loss of
secreted factors that contribute to transformed morphol-
ogy (A. Cox, C. Der, R. Coffey, unpublished results).
Collectively, these data indicate that FTI effects on H-Ras
transformation may involve multiple complex mecha-
nisms, perhaps involving Ras, Ras-related proteins, and
Ras-independent mitogenic signaling pathways.
We have shown that an important mechanism by
which FTIs specifically block H-Ras RIE-1 cellular
proliferation is by reducing EGFR ligand expression.
This observation raises the question as to how essential
EGFR ligands are to the Ras-transformed phenotype of
epithelial cells in general. This may depend on the cell
type under study, the context or stage of carcinogenesis,
and the functional redundancy of the EGFR ligand
family. In contrast to our finding in RIE-1 cells, TGF-a
alone was not able to transform IEC-18 cells, although its
depletion in Ras-transformed IEC-18 cells resulted in
decreased growth.46 Likewise, a role for TGF-a in tumor
promotion in the context of Ras transformation has been
proposed for skin and mammary carcinoma.47,48 A broader
issue is the role of EGFR signaling in Ras transformation
of epithelial cells. In EGFR null keratinocytes, introduc-
tion of oncogenic Ras results in benign tumor formation
in nude mouse grafts.49 However, growth of v-rasHa
papillomas was impaired, suggesting that EGFR signal-
ing may function in tumor promotion rather than
initiation.49 Current studies will address this in the colon
by introduction of oncogenic Ras to a recently established
EGFR null mouse colonocyte cell line (R. Whitehead, D.
Threadgill, and R. Coffey, personal communication).
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George Hoyt Whipple (1878–1976) was born in Ashland, New Hamp-
shire, the son and grandson of country doctors. A boyhood love of the
outdoors lasted throughout his life. As an undergraduate at Yale, he
distinguished himself as a keen athlete. To support his medical studies at
Johns Hopkins he taught at a military academy and in summers worked on
lake steamboats in New Hampshire. His M.D. degree in hand, he became a
lecturer in pathology, then associate professor at Johns Hopkins. In 1909
he described in meticulous detail the fatal course in a young physician of a
previously unrecognized ‘‘lipodystrophy,’’ now known as Whipple’s dis-
ease. In 1914 he returned from a sojourn in Panama gravely ill with
malaria; he was admitted to the Presbyterian Hospital in New York where
he was cared for by a young intern named Allen Whipple who later became
a famous surgeon (no relation, but the two became lifelong friends). On
recovery he was lured to the University of California as professor of research
medicine, where he furthered his growing reputation. In 1921 he accepted
a call to become the founding professor of pathology and dean at the
University of Rochester’s newly established medical school. Much of his
work there centered on the pathophysiology of anemia. With G. R. Minot
and W. P. Murphy of Harvard he shared the 1934 Nobel Prize for
discoveries leading to the treatment of primary pernicious anemia with
liver extract. In tribute to his administration at Rochester, his students
composed a doggerel:
‘‘With wisdom born in New Hampshire hills
And high disdain for useless frills,
He sat him down on a three-legged stool,
And man by man there grew a school.’’
—Contributed by WILLIAM S. HAUBRICH, M.D.
Scripps Clinic and Research Foundation, La Jolla, California
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